Why work with ICER?
ICER is a leader in the field of health technology evaluation and their evaluations are an important contribution to U.S. health care decision-making and the larger conversation about healthcare and value.
What services will the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute provide to Institute for Clinical and Economic Review (ICER)?
The CHOICE team will develop cost-effectiveness models to estimate the cost per outcomes achieved as well per patient cost estimates for ICER generated review topics. The CHOICE will also provide general Health Economics support to projects.
What is the term length of the collaboration with ICER?
The collaboration is ongoing and is renewed every two-years.
What resources will be dedicated to ICER evaluations?
A faculty member with HEOR expertise will lead and be responsible for all aspects of the evaluation. A senior scientist with HEOR expertise will be responsible for the model development and share responsibility for the analysis and reporting of results. A Graduate research assistant will be involved to support all activities.
Will interested stakeholders be allowed to provide comments on the work?
We are committed to our work being transparent and inclusive of stakeholder input and will follow the approach developed by ICER. Specifically, members of the public, payers and manufacturers will be invited to comment on the draft reports during public comment periods. All other communications should be directed to ICER at http://www.icer-review.org/about/contact-us/
What information will be made available to the public?
Information about the model development, methods, data, and results for the work performed by CHOICE will be made publicly available in the ICER-reviews.
Will the UW team follow standard approaches for quality assurance and validation?
Yes, the UW will adhere to the ISPOR guidelines and the ICER reference case.
Will the University of Washington team consider consulting with the drug developer being evaluated?
The University of Washington team will not consult directly with drug developers with models being evaluated during the project phase, except through the communication process established by ICER, which includes multiple points of contact with drug developers throughout the process.
Will the UW team provide consulting advice to the pharmaceutical industry?
We will not provide consulting advice as part of our evaluations for ICER. Any work outside of the ICER collaboration will be subject to a comprehensive financial conflict of interest plan established with the UW office of research.
Can drug developers reach out to UW SOP with clinical information regarding the product that is being evaluated?
ICER’s communication process includes the opportunity for drug companies to provide clinical information to support the evaluations.
Who should we contact for more information?